India Malaria Vaccine Market to Grow with a CAGR of 3.59% through 2030

Increasing Investment in Biotechnology is expected to drive the India malaria vaccine market in the forecast period, 2026-2030.

According to TechSci Research report, “India Malaria Vaccine Market – By Region, Competition Forecast & Opportunities, 2030F”, the India Malaria Vaccine Market stood at USD 38.21 million in 2024 and is anticipated to grow with a CAGR of 3.59% in the forecast period, 2026-2030. This can be ascribed to the rising number of clinical trials along with the increasing investments and support from the government. Also, Indian vaccine manufacturers are collaborating with global partners to develop and manufacture malaria vaccines. For example, the Serum Institute of India has partnered with Codagenix, a US-based biotech company, to develop an intranasal malaria vaccine. 

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "India Malaria Vaccine Market”

The India Malaria Vaccine Market is segmented into vaccine type, route of administration, regional distribution, and company.

Based on vaccine type, pre erythrocytic category is showing the fastest growth in the India Malaria Vaccine market, due to its promising potential in preventing malaria at an early stage of infection. Pre-erythrocytic vaccines target the liver stage of the Plasmodium parasite lifecycle, before the parasite enters red blood cells and causes the clinical symptoms of malaria. By intervening early in the infection process, these vaccines offer a more effective means of preventing the spread of the disease. Given the high transmission rates of malaria in India, particularly in endemic regions, the ability to stop the parasite before it enters the bloodstream is a significant breakthrough. This early intervention can dramatically reduce malaria incidence and mortality, particularly in vulnerable populations such as children and pregnant women. The growing success of clinical trials, alongside ongoing research efforts, is driving the demand for pre-erythrocytic vaccines, positioning this category as a major growth driver in India's malaria vaccine market.

Based on region, North India is witnessing significant growth in the malaria vaccine market due to the region’s persistent malaria burden, especially in states like Uttar Pradesh, Bihar, and Rajasthan. These states experience a higher prevalence of malaria, particularly in rural and remote areas, where access to healthcare and preventive measures like insecticide-treated nets may be limited. The increase in malaria cases in these regions, along with seasonal fluctuations and higher vector breeding sites, makes the need for effective vaccination programs urgent. The significant disease burden has prompted local governments and health organizations to prioritize malaria elimination strategies, boosting the demand for vaccines, particularly for high-risk groups such as children and pregnant women. As a result, North India is emerging as a key market for malaria vaccines, with both public and private sectors actively working to reduce transmission rates. The growing focus on mass immunization campaigns and prevention measures is expected to further accelerate the market’s growth in this region over the forecast period.

Major companies operating in India Malaria Vaccine Market are:

• Gennova Biopharmaceuticals Ltd
• Zydus Group
• Serum Institute of India Private Limited
• Bharat Biotech International Limited
• Indian Immunologicals Limited
• Panacea Biotec
• Mynvax
• Cadila Pharmaceuticals
• Biological E Limited
• Sanofi Pasteur

Download Free Sample Report

Customers can also request for 10% free customization on this report

"The increasing demand for effective and rapid vaccination solutions is significantly driving the growth of the malaria vaccine market in India. As malaria remains a major public health challenge, especially in endemic regions, the need for innovative and reliable vaccines is becoming more critical. The development of malaria vaccines that offer long-term protection, especially in high-risk populations such as children and pregnant women, is essential to reduce disease burden and mortality. The integration of advanced technologies, such as next-generation sequencing, real-time monitoring of vaccine efficacy, and improved manufacturing techniques, is crucial for ensuring the safety, potency, and accessibility of these vaccines. As the market evolves, continuous advancements in research, vaccine delivery systems, and regulatory frameworks will play a key role in accelerating the availability of malaria vaccines across India. These innovations will ultimately transform the landscape of malaria prevention in the country, making vaccination programs more efficient, accessible, and capable of addressing the diverse needs of India's population and healthcare providers," said Mr. Karan Chechi, Research Director of TechSci Research, a research-focused management consulting firm.

“India Malaria Vaccine Market By Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Others), By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others), By Region, Competition Forecast & Opportunities, 2020-2030F”, has evaluated the future growth potential of Global India Malaria Vaccine Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global India Malaria Vaccine Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com